Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
Eli Lilly ( LLY 2.31%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...